Lourdes Riquelme, Author at Labiotech.eu

About

Spanish Biotechnologist with a MS in Genetics from Universidad Autonoma of Barcelona. My interests go from science to fashion and anything in between.

Articles by Lourdes Riquelme

News and Trends 11 May 2015

PhoreMost awarded €1.96M to target the “undruggable” Cancer Genes

Cambridge-based PhoreMost has been selected to receive a funding award of €1.96M (£1.4 million) from the UK’s innovation agency, Innovate UK, to develop its lead oncology programme targeting mutant KRAS cancers. The British company that aims to provide low-priced and more diversed therapeutics, has developed ‘Site-Seeker’, a next-generation phenotypic screening platform based on PhoreMost’s Protein […]

May 11, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 10 May 2015

Succesful Phase III for Indivior’s Schizophrenia treatment

Indivior obtained top-line results from its phase III clinical trial of RBP-7000, a candidate treatment for schizophrenia. Based on these successful outcomes, the company expects to submit a New Drug Application to the U.S. FDA for potential approval in 2017. Schizophrenia is a chronic, severe and disabling brain disorder that affects an estimated 26 million […]

May 10, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 8 May 2015

MorphoSys acquired Lanthio, a Dutch Peptide Therapeutic company

MorphoSys has acquired the Dutch biopharmaceutical company Lanthio Pharma. Morphosys already held 19.98% of Lanthio Pharma and will now pay €20M to purchase all outstanding shares. Thanks to the transaction MorphoSys can add Lanthio Pharma’s lead compound, LP2, to its growing proprietary portfolio. The compound, a novel lanthipeptide in development for diabetic nephropathy and fibrotic […]

May 8, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 7 May 2015

Omeicos is moving forward with the appointment of D. Ulrich Dauer

Omeicos Therapeutics has appointed Dr. Ulrich Dauer as Chief Executive Officer. The company, that recently raised €6.2M, enrolled expert Dr. Dauer to advance on its atrial fibrillation treatment. Dr. Dauer will join Omeicos to bring additional leadership expertise as the company builds the infrastructure and capabilities needed to develop its lead therapeutic candidate for atrial […]

May 7, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 7 May 2015

Gilead acquired epigenetics-expert EpiTherapeutics

Gilead Sciences has acquired the small Danish biotech EpiTherapeutics for €57M. The epigenetics-expert has generated a library of small molecule inhibitors of gene transcription regulation than can be used for certain cancer treatments. The American company announced the signing of a definitive agreement to purchase the Danish company for €57M. EpiTherapeutics is developing innovative cancer […]

May 7, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 6 May 2015

Global Bioenergies produced its First batch of Isobutene in a record time

Global Bioenergies delivered the first batch of isobutene from renewable resources to its partner Arkema six months ahead of the projected schedule. Thanks to the cooperation of ARD’s, an affiliate of the French sugar producer Cristal Union, and Global Bioenergies’ teams, the scaling up of the process in the industrial pilot has been achieved in […]

May 6, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 6 May 2015

Flagship Ventures recruited a Dream Team composed of Astra Zeneca, Bayer and Nestlé

AstraZeneca, Bayer and Nestlé have entered Flagship Ventures’ ranks. The three big-shots will share their know how to support Flagship’s VentureLabs, its start-up incubator. Yet another victory for the American leading VC company that recently banked €478M. On March 26th, Flagship Ventures established its own personal record, putting together €478M in new funds. As Noubar Afeyan, […]

May 6, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 6 May 2015

Kymab secures €79.8 Million to develop its Antibody-Generating technology

British Kymab raised an additional €44.4M to its already very successful Series B financing. The cash was courtesy of Woodford Patient Capital Trust and Malin Corporation, which joined the Wellcome Trust and the Bill&Melinda Gates Foundation, the previous investors. The British biotech, a monoclonal antibody biopharmaceutical company, successfully raised an additional €44.4M to complete a […]

May 6, 2015 - 2 minutesmins - By Lourdes Riquelme

thrombosis bayer healthcare isis pharmaceuticals

News and Trends 5 May 2015

Isis Pharmaceuticals and Bayer HealthCare team up to prevent thrombosis

Isis Pharmaceuticals and Bayer HealthCare will develop and commercialize ISIS-FXIRx for the prevention of thrombosis. The German Pharma will provide up to €139M to Isis, including an up-front payment of €89.6M. Under the terms of the agreement, Isis is eligible to receive up to €139M in near-term payments, including an immediate €89.6M up-front payment and […]

May 5, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 5 May 2015

Natural Killer therapies for Cancer: a Fast-Evolving field

Natural killers are an emerging approach to fight inflammatory diseases and cancer. These immune actors, that specifically regulate the activity of the immune system, are attracting the attention of several small startups and more than a few big Pharmas. The immune system includes a set of body defenses, that fight foreign forms. But external bodies aren’t […]

May 5, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 4 May 2015

Karolinska Development took a Step Back in its Biotech portfolio

The finances of Karolinska Development remain in a dangerous downward spiral as the company dropped to €136.9M (SEK 1,277 million), an unsatisfactory record for the company, the lowest valuation since 2011. For this purpose, the company decided to totally abandon investing in Pergamum, Umecrine and NeoDynamics AB, three biotech companies. Karolinska’s reaction is well-defined: the […]

May 4, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 4 May 2015

Sygnis on the way to conquer the UK Life Sciences market

Sygnis signed a distribution agreement with Cambridge Bioscience for the commercialization of its proprietary product portfolio in the UK and Ireland. This is a significant expansion of product roll-out into one of the most important life science markets in Europe. Under the terms and conditions of the agreement, Cambridge Bioscience will promote, market, sell and […]

May 4, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Lourdes Riquelme

About

Articles by Lourdes Riquelme

PhoreMost awarded €1.96M to target the “undruggable” Cancer Genes

Succesful Phase III for Indivior’s Schizophrenia treatment

MorphoSys acquired Lanthio, a Dutch Peptide Therapeutic company

Omeicos is moving forward with the appointment of D. Ulrich Dauer

Gilead acquired epigenetics-expert EpiTherapeutics

Global Bioenergies produced its First batch of Isobutene in a record time

Flagship Ventures recruited a Dream Team composed of Astra Zeneca, Bayer and Nestlé

Kymab secures €79.8 Million to develop its Antibody-Generating technology

Isis Pharmaceuticals and Bayer HealthCare team up to prevent thrombosis

Natural Killer therapies for Cancer: a Fast-Evolving field

Karolinska Development took a Step Back in its Biotech portfolio

Sygnis on the way to conquer the UK Life Sciences market

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Lourdes Riquelme

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!